Breaking bottlenecks in drug development has potential to revolutionize industry

Many new drugs show great promise in laboratory trials, but they often have poor solubility or fail to reach their targeted site. This joint project between Åbo Akademi and Bayer uses microfluidics technology to develop surface-functionalized, nanosized drug crystals for more accurate and targeted drug delivery. Improved drug solubility and targeting contributes to improved drug efficacy and safety. The collaborative setting will facilitate the transfer of academic discoveries directly into commercial product development. In this way the project could have momentous impact on pharmaceuticals development globally.